Physician profile
Eliza Lenihan
NPI 1962298059
$1,640.37
in general payments reported to CMS, 2019-2025
32 companies · $1,640 in 2025
The $1,640 reported for 2025 was more than what 91% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,482 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,482.38 |
| Education | $157.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $221.40 | 2025 | Rybrevant, Carvykti, Tecvayli |
| Glaxosmithkline, LLC. | $158.61 | 2025 | Ojjaara, Blenrep |
| Novartis Pharmaceuticals Corporation | $123.04 | 2025 | |
| Genzyme Corporation | $107.31 | 2025 | |
| Aveo Pharmaceuticals, INC. | $93.63 | 2025 | |
| Seagen INC. | $80.00 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $70.64 | 2025 | Imfinzi, Lynparza |
| Incyte Corporation | $64.86 | 2025 | Jakafi |
| Beone Medicines USA, INC. | $59.89 | 2025 | Brukinsa, Tevimbra |
| Daiichi Sankyo INC. | $59.60 | 2025 | Enhertu |
| Geron Corporation | $54.57 | 2025 | Rytelo |
| Legend Biotech USA INC. | $50.64 | 2025 | Carvykti |
| Emd Serono, INC. | $34.17 | 2025 | |
| Tersera Therapeutics LLC | $31.68 | 2025 | Zoladex |
| Merck Sharp & Dohme LLC | $30.50 | 2025 | Keytruda, Keytruda Qlex, Welireg |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.46 | 2025 | |
| Deciphera Pharmaceuticals INC. | $29.97 | 2025 | Qinlock, Romvimza |
| Rigel Pharmaceuticals, INC. | $29.85 | 2025 | Tavalisse, Gavreto, Rezlidhia |
| Sobi, INC | $29.50 | 2025 | |
| Coherus Oncology, INC. | $27.25 | 2025 | Loqtorzi |
| Kyowa Kirin, INC. | $26.53 | 2025 | |
| Lilly USA, LLC | $25.82 | 2025 | Verzenio |
| Azurity Pharmaceuticals, INC. | $25.15 | 2025 | Danziten |
| Iovance Biotherapeutics, INC. | $23.68 | 2025 | Amtagvi |
| Amneal Pharmaceuticals LLC | $23.63 | 2025 | Alymsys |
| Puma Biotechnology, INC. | $23.31 | 2025 | |
| Jazz Pharmaceuticals INC. | $22.42 | 2025 | |
| Gilead Sciences, INC. | $18.66 | 2025 | Trodelvy |
| Recordati_rare_diseases_inc. | $18.49 | 2025 | Enjaymo |
| Celgene Corporation | $17.29 | 2025 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $14.25 | 2025 | |
| Shorla Oncology INC. | $13.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eliza Lenihan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.